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CLINICAL STUDY OF ENDOCRINE THERAPY IN STAGE B 
AND C PROST ATE CANCER 
Takatoshi UEI， Hiroshi OKAZAKI， Toshiyuki NAKAMURA and Nobuo KATOU 
From the Dψartment 01 Urology， TatebりashiKousei Hospital 
Kazuhiro SUZUKI and Hidetoshi Y AMANAKA 
From the Dψartment 01 Urology， Gunma University School 01 Medicine 
To evaluate the usefulness of endocrine therapy for stage B and C prostate cancer， we carried out a 
retrospective study on overall survival rate， cause-specific survival， PSA recurrence-free rate， and their 
predictive factors in 118 patients with stage B prostate cancer， 61 with stage C prostate cancer who 
underwent endocrine therapy at our department between 1985 and 2001. The cause-specific survival 
rate and PSA recurrence-free rate of stage B patients who underwent endocrine therapy were well， and 
they will take a good clinical course. Thus， inthis stage ofprostate cancer， aged patients and patients 
with complications may be good candidates for endocrine therapy. The cause-specific survival rate 
and PSA recurrence-free rate in the stage C patients who underwent endocrine therapy were 
significantly low. In stage C patients， endocrine therapy should be combined early with other 
methods such as radiotherapy. In the stage B patients who underwent endocrine therapy， PSA and 
Gleason score appeared to be associated with the cause-specific survival rate and PSA recurrence-free 
rate 
(Acta Urol. Jpn. 49: 639-643， 2003) 
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出し， 2群問の統計学的有意差検定には generalized








た.診断時 PSAは病期 B:平均 22.7ng/ml (中央
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Fig. 3. PSA recurrence-free rate in stage B and C prostate cancer. 
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非再発率の予測因子を診断時 PSA，G1eason score， 
年齢， PSに関して検討した.病期Bの疾患特異生
存率に閲しては， PSA孟10ng/mlと孟50ng/ml， 
Gleason score壬6とミ8および Gleasonscore 7と
主8において有意差をもっておのおの前者が良好で、
あった (Fig.4A， B). また PSA非再発率に関しで
も， PSA孟10ng/mlと孟50ng/ml， Gleason score 
孟6と注8において有意差をもって前者が良好であ
り，特に PSAにおいては低いほど良好な傾向が認め
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て， PSA， Gleason scoreが疾患特異生存率， PSA非
上井，ほか:前立腺癌 内分泌療法 643 
再発率に影響を与えていると考えられた.
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